<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30674624</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><Issue>7</Issue><PubDate><Year>2019</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Validating Enterovirus D68-2A<sup>pro</sup> as an Antiviral Drug Target and the Discovery of Telaprevir as a Potent D68-2A<sup>pro</sup> Inhibitor.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e02221-18</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.02221-18</ELocationID><Abstract><AbstractText>Enterovirus D68 (EV-D68) is a viral pathogen that leads to severe respiratory illness and has been linked with the development of acute flaccid myelitis (AFM) in children. No vaccines or antivirals are currently available for EV-D68 infection, and treatment options for hospitalized patients are limited to supportive care. Here, we report the expression of the EV-D68 2A protease (2A<sup>pro</sup>) and characterization of its enzymatic activity. Furthermore, we discovered that telaprevir, an FDA-approved drug used for the treatment of hepatitis C virus (HCV) infections, is a potent antiviral against EV-D68 by targeting the 2A<sup>pro</sup> enzyme. Using a fluorescence resonance energy transfer-based substrate cleavage assay, we showed that the purified EV-D68 2A<sup>pro</sup> has proteolytic activity selective against a peptide sequence corresponding to the viral VP1-2A polyprotein junction. Telaprevir inhibits EV-D68 2A<sup>pro</sup> through a nearly irreversible, biphasic binding mechanism. In cell culture, telaprevir showed submicromolar-to-low-micromolar potency against several recently circulating neurotropic strains of EV-D68 in different human cell lines. To further confirm the antiviral drug target, serial viral passage experiments were performed to select for resistance against telaprevir. An N84T mutation near the active site of 2A<sup>pro</sup> was identified in resistant viruses, and this mutation reduced the potency of telaprevir in both the enzymatic and cellular antiviral assays. Collectively, we report for the first time the <i>in vitro</i> enzymatic activity of EV-D68 2A<sup>pro</sup> and the identification of telaprevir as a potent EV-D68 2A<sup>pro</sup> inhibitor. These findings implicate EV-D68 2A<sup>pro</sup> as an antiviral drug target and highlight the repurposing potential of telaprevir to treat EV-D68 infection.<b>IMPORTANCE</b> A 2014 EV-D68 outbreak in the United States has been linked to the development of acute flaccid myelitis in children. Unfortunately, no treatment options against EV-D68 are currently available, and the development of effective therapeutics is urgently needed. Here, we characterize and validate a new EV-D68 drug target, the 2A<sup>pro</sup>, and identify telaprevir-an FDA-approved drug used to treat hepatitis C virus (HCV) infections-as a potent antiviral with a novel mechanism of action toward 2A<sup>pro</sup> 2A<sup>pro</sup> functions as a viral protease that cleaves a peptide sequence corresponding to the VP1-2A polyprotein junction. The binding of telaprevir potently inhibits its enzymatic activity, and using drug resistance selection, we show that the potent antiviral activity of telaprevir was due to 2A<sup>pro</sup> inhibition. This is the first inhibitor to selectively target the 2A<sup>pro</sup> from EV-D68 and can be used as a starting point for the development of therapeutics with selective activity against EV-D68.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 American Society for Microbiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Musharrafieh</LastName><ForeName>Rami</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, Arizona, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry and Biochemistry, The University of Arizona, Tucson, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Chunlong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jiantao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yanmei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diesing</LastName><ForeName>Jessica M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Biochemistry, The University of Arizona, Tucson, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marty</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Biochemistry, The University of Arizona, Tucson, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4845-4621</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, Arizona, USA junwang@pharmacy.arizona.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 AI119187</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R33 AI119187</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 GM128624</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008804</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009842">Oligopeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>655M5O3W0U</RegistryNumber><NameOfSubstance UI="C486464">telaprevir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000072283" MajorTopicYN="N">A549 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030016" MajorTopicYN="N">Enterovirus D, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009842" MajorTopicYN="N">Oligopeptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antiviral agents</Keyword><Keyword MajorTopicYN="N">antiviral pharmacology</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">protease inhibitors</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>9</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30674624</ArticleId><ArticleId IdType="pmc">PMC6430540</ArticleId><ArticleId IdType="doi">10.1128/JVI.02221-18</ArticleId><ArticleId IdType="pii">JVI.02221-18</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Holm-Hansen CC, Midgley SE, Fischer TK. 2016. Global emergence of enterovirus D68: a systematic review. Lancet Infect Dis 16:e64&#x2013;e75. doi:10.1016/S1473-3099(15)00543-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(15)00543-5</ArticleId><ArticleId IdType="pubmed">26929196</ArticleId></ArticleIdList></Reference><Reference><Citation>Midgley CM, Watson JT, Nix WA, Curns AT, Rogers SL, Brown BA, Conover C, Dominguez SR, Feikin DR, Gray S, Hassan F, Hoferka S, Jackson MA, Johnson D, Leshem E, Miller L, Nichols JB, Nyquist AC, Obringer E, Patel A, Patel M, Rha B, Schneider E, Schuster JE, Selvarangan R, Seward JF, Turabelidze G, Oberste MS, Pallansch MA, Gerber SI, EV-D68 Working Group . 2015. Severe respiratory illness associated with a nationwide outbreak of enterovirus D68 in the USA (2014): a descriptive epidemiological investigation. Lancet Respir Med 3:879&#x2013;887. doi:10.1016/S2213-2600(15)00335-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(15)00335-5</ArticleId><ArticleId IdType="pmc">PMC5693332</ArticleId><ArticleId IdType="pubmed">26482320</ArticleId></ArticleIdList></Reference><Reference><Citation>Oermann CM, Schuster JE, Conners GP, Newland JG, Selvarangan R, Jackson MA. 2015. Enterovirus d68. A focused review and clinical highlights from the 2014 U.S. outbreak. Ann Am Thorac Soc 12:775&#x2013;781. doi:10.1513/AnnalsATS.201412-592FR.</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.201412-592FR</ArticleId><ArticleId IdType="pubmed">25714788</ArticleId></ArticleIdList></Reference><Reference><Citation>Messacar K, Schreiner TL, Maloney JA, Wallace A, Ludke J, Oberste MS, Nix WA, Robinson CC, Glode MP, Abzug MJ, Dominguez SR. 2015. A cluster of acute flaccid paralysis and cranial nerve dysfunction temporally associated with an outbreak of enterovirus D68 in children in Colorado, USA. Lancet 385:1662&#x2013;1671. doi:10.1016/S0140-6736(14)62457-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)62457-0</ArticleId><ArticleId IdType="pubmed">25638662</ArticleId></ArticleIdList></Reference><Reference><Citation>Messacar K, Asturias EJ, Hixon AM, Van Leer-Buter C, Niesters HGM, Tyler KL, Abzug MJ, Dominguez SR. 2018. Enterovirus D68 and acute flaccid myelitis&#x2014;evaluating the evidence for causality. Lancet Infect Dis 18:e239&#x2013;e247. doi:10.1016/S1473-3099(18)30094-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(18)30094-X</ArticleId><ArticleId IdType="pmc">PMC6778404</ArticleId><ArticleId IdType="pubmed">29482893</ArticleId></ArticleIdList></Reference><Reference><Citation>Greninger AL, Naccache SN, Messacar K, Clayton A, Yu G, Somasekar S, Federman S, Stryke D, Anderson C, Yagi S, Messenger S, Wadford D, Xia D, Watt JP, Van Haren K, Dominguez SR, Glaser C, Aldrovandi G, Chiu CY. 2015. A novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA (2012-14): a retrospective cohort study. Lancet Infect Dis 15:671&#x2013;682. doi:10.1016/S1473-3099(15)70093-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(15)70093-9</ArticleId><ArticleId IdType="pmc">PMC6027625</ArticleId><ArticleId IdType="pubmed">25837569</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrey JD, Wang H, Hurst BL, Zukor K, Siddharthan V, Van Wettere AJ, Sinex DG, Tarbet EB. 2018. Causation of acute flaccid paralysis by myelitis and myositis in enterovirus-D68 infected mice deficient in interferon alphabeta/gamma receptor deficient mice. Viruses 10:E33. doi:10.3390/v10010033.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v10010033</ArticleId><ArticleId IdType="pmc">PMC5795446</ArticleId><ArticleId IdType="pubmed">29329211</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J, Thibaut HJ, Strating J, van Kuppeveld FJM. 2018. The life cycle of non-polio enteroviruses and how to target it. Nat Rev Microbiol 16:368&#x2013;381. doi:10.1038/s41579-018-0005-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0005-4</ArticleId><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Linden L, Wolthers KC, van Kuppeveld FJ. 2015. Replication and inhibitors of enteroviruses and parechoviruses. Viruses 7:4529&#x2013;4562. doi:10.3390/v7082832.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7082832</ArticleId><ArticleId IdType="pmc">PMC4576193</ArticleId><ArticleId IdType="pubmed">26266417</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulferts R, van der Linden L, Thibaut HJ, Lanke KH, Leyssen P, Coutard B, De Palma AM, Canard B, Neyts J, van Kuppeveld FJ. 2013. Selective serotonin reuptake inhibitor fluoxetine inhibits replication of human enteroviruses B and D by targeting viral protein 2C. Antimicrob Agents Chemother 57:1952&#x2013;1956. doi:10.1128/AAC.02084-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.02084-12</ArticleId><ArticleId IdType="pmc">PMC3623316</ArticleId><ArticleId IdType="pubmed">23335743</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhoden E, Zhang M, Nix WA, Oberste MS. 2015. In vitro efficacy of antiviral compounds against enterovirus D68. Antimicrob Agents Chemother 59:7779&#x2013;7781. doi:10.1128/AAC.00766-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00766-15</ArticleId><ArticleId IdType="pmc">PMC4649146</ArticleId><ArticleId IdType="pubmed">26149998</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulferts R, de Boer SM, van der Linden L, Bauer L, Lyoo HR, Mate MJ, Lichiere J, Canard B, Lelieveld D, Omta W, Egan D, Coutard B, van Kuppeveld FJ. 2016. Screening of a library of FDA-approved drugs identifies several enterovirus replication inhibitors that target viral protein 2C. Antimicrob Agents Chemother 60:2627&#x2013;2638. doi:10.1128/AAC.02182-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.02182-15</ArticleId><ArticleId IdType="pmc">PMC4862474</ArticleId><ArticleId IdType="pubmed">26856848</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Q, Yuan S, Zhang C, Wang Y, Wang Y, He G, Zhang S, Altmeyer R, Zou G. 2015. Discovery of itraconazole with broad-spectrum in vitro antienterovirus activity that targets nonstructural protein 3A. Antimicrob Agents Chemother 59:2654&#x2013;2665. doi:10.1128/AAC.05108-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.05108-14</ArticleId><ArticleId IdType="pmc">PMC4394834</ArticleId><ArticleId IdType="pubmed">25691649</ArticleId></ArticleIdList></Reference><Reference><Citation>Messacar K, Sillau S, Hopkins SE, Otten C, Wilson-Murphy M, Wong B, Santoro JD, Treister A, Bains HK, Torres A, Zabrocki L, Glanternik JR, Hurst AL, Martin JA, Schreiner T, Makhani N, DeBiasi RL, Kruer MC, Tremoulet AH, Van Haren K, Desai J, Benson LA, Gorman MP, Abzug MJ, Tyler KL, Dominguez SR. 9 November 2018. Safety, tolerability, and efficacy of fluoxetine as an antiviral for acute flaccid myelitis. Neurology doi:10.1212/WNL.0000000000006670.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006670</ArticleId><ArticleId IdType="pmc">PMC6512883</ArticleId><ArticleId IdType="pubmed">30413631</ArticleId></ArticleIdList></Reference><Reference><Citation>Skern T, Hamp&#xf6;lz B, Guarne A, Fita I, Bergmann E, Petersen J, James MNG. 2002. Structure and function of picornavirus proteinases, p 199&#x2013;212. In Semler BL, Wimmer E (ed), Molecular biology of picornaviruses. ASM Press, Washington, DC.</Citation></Reference><Reference><Citation>Mosimann SC, Cherney MM, Sia S, Plotch S, James MN. 1997. Refined X-ray crystallographic structure of the poliovirus 3C gene product. J Mol Biol 273:1032&#x2013;1047. doi:10.1006/jmbi.1997.1306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jmbi.1997.1306</ArticleId><ArticleId IdType="pubmed">9367789</ArticleId></ArticleIdList></Reference><Reference><Citation>Allaire M, Chernaia MM, Malcolm BA, James MN. 1994. Picornaviral 3C cysteine proteinases have a fold similar to chymotrypsin-like serine proteinases. Nature 369:72&#x2013;76. doi:10.1038/369072a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/369072a0</ArticleId><ArticleId IdType="pubmed">8164744</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews DA, Smith WW, Ferre RA, Condon B, Budahazi G, Sisson W, Villafranca JE, Janson CA, McElroy HE, Gribskov CL. 1994. Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein. Cell 77:761&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pubmed">7515772</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui S, Wang J, Fan T, Qin B, Guo L, Lei X, Wang J, Wang M, Jin Q. 2011. Crystal structure of human enterovirus 71 3C protease. J Mol Biol 408:449&#x2013;461. doi:10.1016/j.jmb.2011.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2011.03.007</ArticleId><ArticleId IdType="pmc">PMC7094522</ArticleId><ArticleId IdType="pubmed">21396941</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J, George S, Kusov Y, Perbandt M, Anemuller S, Mesters JR, Norder H, Coutard B, Lacroix C, Leyssen P, Neyts J, Hilgenfeld R. 2013. 3C protease of enterovirus 68: structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses. J Virol 87:4339&#x2013;4351. doi:10.1128/JVI.01123-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01123-12</ArticleId><ArticleId IdType="pmc">PMC3624371</ArticleId><ArticleId IdType="pubmed">23388726</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee W, Watters KE, Troupis AT, Reinen NM, Suchy FP, Moyer KL, Frederick RO, Tonelli M, Aceti DJ, Palmenberg AC, Markley JL. 2014. Solution structure of the 2A protease from a common cold agent, human rhinovirus C2, strain W12. PLoS One 9:e97198. doi:10.1371/journal.pone.0097198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0097198</ArticleId><ArticleId IdType="pmc">PMC4061012</ArticleId><ArticleId IdType="pubmed">24937088</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxter NJ, Roetzer A, Liebig HD, Sedelnikova SE, Hounslow AM, Skern T, Waltho JP. 2006. Structure and dynamics of coxsackievirus B4 2A proteinase, an enzyme involved in the etiology of heart disease. J Virol 80:1451&#x2013;1462. doi:10.1128/JVI.80.3.1451-1462.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.80.3.1451-1462.2006</ArticleId><ArticleId IdType="pmc">PMC1346940</ArticleId><ArticleId IdType="pubmed">16415022</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Q, Yameen M, Liu W, Gao Z, Li Y, Peng X, Cai Y, Wu C, Zheng Q, Li J, Lin T. 2013. Conformational plasticity of the 2A proteinase from enterovirus 71. J Virol 87:7348&#x2013;7356. doi:10.1128/JVI.03541-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03541-12</ArticleId><ArticleId IdType="pmc">PMC3700279</ArticleId><ArticleId IdType="pubmed">23616646</ArticleId></ArticleIdList></Reference><Reference><Citation>Stempniak M, Hostomska Z, Nodes BR, Hostomsky Z. 1997. The NS3 proteinase domain of hepatitis C virus is a zinc-containing enzyme. J Virol 71:2881&#x2013;2886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC191414</ArticleId><ArticleId IdType="pubmed">9060645</ArticleId></ArticleIdList></Reference><Reference><Citation>De Clercq E, Li G. 2016. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev 29:695&#x2013;747. doi:10.1128/CMR.00102-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00102-15</ArticleId><ArticleId IdType="pmc">PMC4978613</ArticleId><ArticleId IdType="pubmed">27281742</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang CY, Huang AC, Hour MJ, Huang SH, Kung SH, Chen CH, Chen IC, Chang YS, Lien JC, Lin CW. 2015. Antiviral potential of a novel compound CW-33 against enterovirus A71 via inhibition of viral 2A protease. Viruses 7:3155&#x2013;3171. doi:10.3390/v7062764.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7062764</ArticleId><ArticleId IdType="pmc">PMC4488731</ArticleId><ArticleId IdType="pubmed">26090728</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyoda H, Nicklin MJ, Murray MG, Anderson CW, Dunn JJ, Studier FW, Wimmer E. 1986. A second virus-encoded proteinase involved in proteolytic processing of poliovirus polyprotein. Cell 45:761&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">3011278</ArticleId></ArticleIdList></Reference><Reference><Citation>Maghsoudi N, Khodagholi F, Sadjadi M, Zeinodini M, Sabbaghian M. 2008. Purification and partial characterization of coxsackievirus B3 2A protease expressed in Escherichia coli. Int J Biol Macromol 43:238&#x2013;244. doi:10.1016/j.ijbiomac.2008.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2008.05.008</ArticleId><ArticleId IdType="pubmed">18590760</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommergruber W, Zorn M, Blaas D, Fessl F, Volkmann P, Maurer-Fogy I, Pallai P, Merluzzi V, Matteo M, Skern T. 1989. Polypeptide 2A of human rhinovirus type 2: identification as a protease and characterization by mutational analysis. Virology 169:68&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">2538037</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown DM, Hixon AM, Oldfield LM, Zhang Y, Novotny M, Wang W, Das SR, Shabman RS, Tyler KL, Scheuermann RH. 2018. Contemporary circulating enterovirus D68 strains have acquired the capacity for viral entry and replication in human neuronal cells. mBio 9:e01954-18. doi:10.1128/mBio.01954-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.01954-18</ArticleId><ArticleId IdType="pmc">PMC6191546</ArticleId><ArticleId IdType="pubmed">30327438</ArticleId></ArticleIdList></Reference><Reference><Citation>Peroutka RJ III, Orcutt SJ, Strickler JE, Butt TR. 2011. SUMO fusion technology for enhanced protein expression and purification in prokaryotes and eukaryotes. Methods Mol Biol 705:15&#x2013;30. doi:10.1007/978-1-61737-967-3_2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-61737-967-3_2</ArticleId><ArticleId IdType="pubmed">21125378</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores MV, Strawbridge J, Ciaramella G, Corbau R. 2009. HCV-NS3 inhibitors: determination of their kinetic parameters and mechanism. Biochim Biophys Acta 1794:1441&#x2013;1448. doi:10.1016/j.bbapap.2009.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbapap.2009.06.004</ArticleId><ArticleId IdType="pubmed">19505593</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker D, Kaczmarska Z, Arkona C, Schulz R, Tauber C, Wolber G, Hilgenfeld R, Coll M, Rademann J. 2016. Irreversible inhibitors of the 3C protease of coxsackie virus through templated assembly of protein-binding fragments. Nat Commun 7:12761. doi:10.1038/ncomms12761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12761</ArticleId><ArticleId IdType="pmc">PMC5052702</ArticleId><ArticleId IdType="pubmed">27677239</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz R, Atef A, Becker D, Gottschalk F, Tauber C, Wagner S, Arkona C, Abdel-Hafez AA, Farag HH, Rademann J, Wolber G. 2018. Phenylthiomethyl ketone-based fragments show selective and irreversible inhibition of enteroviral 3C proteases. J Med Chem 61:1218&#x2013;1230. doi:10.1021/acs.jmedchem.7b01440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.7b01440</ArticleId><ArticleId IdType="pubmed">29328649</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen TC, Chang HY, Lin PF, Chern JH, Hsu JT, Chang CY, Shih SR. 2009. Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71. Antimicrob Agents Chemother 53:2740&#x2013;2747. doi:10.1128/AAC.00101-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00101-09</ArticleId><ArticleId IdType="pmc">PMC2704669</ArticleId><ArticleId IdType="pubmed">19414569</ArticleId></ArticleIdList></Reference><Reference><Citation>Musharrafieh R, Ma C, Wang J. 2018. Profiling the in vitro drug-resistance mechanism of influenza A viruses towards the AM2-S31N proton channel blockers. Antiviral Res 153:10&#x2013;22. doi:10.1016/j.antiviral.2018.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2018.03.002</ArticleId><ArticleId IdType="pmc">PMC5891360</ArticleId><ArticleId IdType="pubmed">29518414</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C, Zhang J, Wang J. 2016. Pharmacological characterization of the spectrum of antiviral activity and genetic barrier to drug resistance of M2-S31N channel blockers. Mol Pharmacol 90:188&#x2013;198. doi:10.1124/mol.116.105346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.116.105346</ArticleId><ArticleId IdType="pmc">PMC4998667</ArticleId><ArticleId IdType="pubmed">27385729</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo J, Kye S, Quinn KK, Cooper P, Damoiseaux R, Krogstad P. 2015. Discovery of structurally diverse small-molecule compounds with broad antiviral activity against enteroviruses. Antimicrob Agents Chemother 60:1615&#x2013;1626. doi:10.1128/AAC.02646-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.02646-15</ArticleId><ArticleId IdType="pmc">PMC4775951</ArticleId><ArticleId IdType="pubmed">26711750</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan M, Gao S, Zhou Z, Zhang K, Liu S, Wang Z, Wang T. 2018. A reverse genetics system for enterovirus D68 using human RNA polymerase I. Virus Genes 54:484&#x2013;492. doi:10.1007/s11262-018-1570-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11262-018-1570-3</ArticleId><ArticleId IdType="pubmed">29777445</ArticleId></ArticleIdList></Reference><Reference><Citation>Niesen FH, Berglund H, Vedadi M. 2007. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc 2:2212&#x2013;2221. doi:10.1038/nprot.2007.321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2007.321</ArticleId><ArticleId IdType="pubmed">17853878</ArticleId></ArticleIdList></Reference><Reference><Citation>Senisterra G, Chau I, Vedadi M. 2012. Thermal denaturation assays in chemical biology. Assay Drug Dev Technol 10:128&#x2013;136. doi:10.1089/adt.2011.0390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/adt.2011.0390</ArticleId><ArticleId IdType="pubmed">22066913</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano KP, Ali A, Aydin C, Soumana D, Ozen A, Deveau LM, Silver C, Cao H, Newton A, Petropoulos CJ, Huang W, Schiffer CA. 2012. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog 8:e1002832. doi:10.1371/journal.ppat.1002832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002832</ArticleId><ArticleId IdType="pmc">PMC3406087</ArticleId><ArticleId IdType="pubmed">22910833</ArticleId></ArticleIdList></Reference><Reference><Citation>Cady SD, Wang J, Wu Y, DeGrado WF, Hong M. 2011. Specific binding of adamantane drugs and direction of their polar amines in the pore of the influenza M2 transmembrane domain in lipid bilayers and dodecylphosphocholine micelles determined by NMR spectroscopy. J Am Chem Soc 133:4274&#x2013;4284. doi:10.1021/ja102581n.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja102581n</ArticleId><ArticleId IdType="pmc">PMC3078525</ArticleId><ArticleId IdType="pubmed">21381693</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh J, Petter RC, Baillie TA, Whitty A. 2011. The resurgence of covalent drugs. Nat Rev Drug Discov 10:307&#x2013;317. doi:10.1038/nrd3410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3410</ArticleId><ArticleId IdType="pubmed">21455239</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Fu B, Li W, Patil G, Liu L, Dorf ME, Li S. 2017. Comparative influenza protein interactomes identify the role of plakophilin 2 in virus restriction. Nat Commun 8:13876. doi:10.1038/ncomms13876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms13876</ArticleId><ArticleId IdType="pmc">PMC5309701</ArticleId><ArticleId IdType="pubmed">28169297</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid DJ, Diesing JM, Miller MA, Perry SM, Wales JA, Montfort WR, Marty MT. 2018. MetaUniDec: high-throughput deconvolution of native mass spectra. J Am Soc Mass Spectrom 30:118&#x2013;127. doi:10.1007/s13361-018-1951-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13361-018-1951-9</ArticleId><ArticleId IdType="pmc">PMC6192864</ArticleId><ArticleId IdType="pubmed">29667162</ArticleId></ArticleIdList></Reference><Reference><Citation>Marty MT, Baldwin AJ, Marklund EG, Hochberg GK, Benesch JL, Robinson CV. 2015. Bayesian deconvolution of mass and ion mobility spectra: from binary interactions to polydisperse ensembles. Anal Chem 87:4370&#x2013;4376. doi:10.1021/acs.analchem.5b00140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.5b00140</ArticleId><ArticleId IdType="pmc">PMC4594776</ArticleId><ArticleId IdType="pubmed">25799115</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>